Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate Curative Therapy vs Conservative Treatment in Older Men With High-risk Prostate Cancer
NCT05448547Phase 3Recruiting
- Start
- Nov 2022
- Primary completion
- Dec 2029
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) (2 arms). Primary endpoints: Overall survival at 10 years and Burden of disease at 10 years. Started Nov 2022; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05448547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448547.